{"id":3920,"date":"2016-04-28T14:51:01","date_gmt":"2016-04-28T14:51:01","guid":{"rendered":"https:\/\/www.nanexa.com\/mfn_news\/kallelse-till-arsstamma-i-nanexa-ab-publ-2\/"},"modified":"2016-04-28T14:51:01","modified_gmt":"2016-04-28T14:51:01","slug":"kallelse-till-arsstamma-i-nanexa-ab-publ-2","status":"publish","type":"mfn_news","link":"https:\/\/nanexa.com\/sv\/mfn_news\/kallelse-till-arsstamma-i-nanexa-ab-publ-2\/","title":{"rendered":"Kallelse till \u00e5rsst\u00e4mma i Nanexa AB (publ)"},"content":{"rendered":"
\n

Aktie\u00e4garna i Nanexa AB(publ) kallas h\u00e4rmed till \u00e5rsst\u00e4mma i Nanexa AB (publ), 556833-0285, torsdagen den 26 maj 2016, klockan 17.00 p\u00e5 Uppsala Business Park, Rapsgatan 7, Uppsala.<\/strong><\/span><\/p>\n<\/div>\n

A. R\u00e4tt att delta p\u00e5 \u00e5rsst\u00e4mman<\/strong> <\/span><\/p>\n

Aktie\u00e4gare som \u00f6nskar delta vid st\u00e4mman ska dels vara inf\u00f6rd i den av Euroclear Sweden AB f\u00f6rda aktieboken per fredagen den 20 maj 2016, och dels anm\u00e4la sin avsikt att delta i bolagsst\u00e4mman senast den 20 maj 2016 under adress: Nanexa AB, Virdings All\u00e9 32 B, 754 50 Uppsala, via e-post till info@nanexa.se eller per telefon 018-100\u00a0300.<\/span><\/p>\n

Vid anm\u00e4lan ska aktie\u00e4garen uppge namn, person- eller organisationsnummer, adress, telefonnummer, e-postadress, eventuella bitr\u00e4den, samt uppgifter om aktieinnehav. Aktie\u00e4gare som f\u00f6retr\u00e4ds genom ombud ska utf\u00e4rda dagtecknad fullmakt f\u00f6r ombudet. Fullmaktsformul\u00e4r h\u00e5lls tillg\u00e4ngligt p\u00e5 Bolagets hemsida www.nanexa.com. Aktie\u00e4gare som har sina aktier f\u00f6rvaltarregistrerade genom banks notariatavdelning eller annan f\u00f6rvaltare m\u00e5ste, f\u00f6r att \u00e4ga r\u00e4tt att delta vid st\u00e4mman, tillf\u00e4lligt inregistrera aktierna i eget namn hos Euroclear Sweden AB. S\u00e5dan registrering m\u00e5ste vara genomf\u00f6rd per 20 maj 2016 och f\u00f6rvaltaren b\u00f6r s\u00e5ledes underr\u00e4ttas i god tid f\u00f6re n\u00e4mnda datum. Om fullmakt utf\u00e4rdas av juridisk person ska bestyrkt kopia av registreringsbevis eller motsvarande f\u00f6r den juridiska personen bifogas. Fullmakt g\u00e4ller ett \u00e5r fr\u00e5n utf\u00e4rdandet eller den l\u00e4ngre giltighetstid som framg\u00e5r av fullmakten, dock h\u00f6gst fem \u00e5r.<\/span><\/p>\n

B. \u00c4renden p\u00e5 st\u00e4mman<\/strong><\/span><\/p>\n

<\/strong>1. \u00d6ppnande av st\u00e4mman
2. Val av ordf\u00f6rande vid st\u00e4mman
3. Uppr\u00e4ttande och godk\u00e4nnande av r\u00f6stl\u00e4ngd
4. Val av en eller tv\u00e5 justeringsm\u00e4n
5. Pr\u00f6vning av om st\u00e4mman blivit beh\u00f6rigen sammankallad
6. Godk\u00e4nnande av dagordningen
7. Framl\u00e4ggande av \u00e5rsredovisningen och revisionsber\u00e4ttelsen
8. Verkst\u00e4llande direkt\u00f6rens anf\u00f6rande
9. Beslut om
a) fastst\u00e4llelse av resultatr\u00e4kningen och balansr\u00e4kningen
b) dispositioner betr\u00e4ffande bolagets vinst eller f\u00f6rlust enligt den fastst\u00e4llda balansr\u00e4kningen
c) ansvarsfrihet f\u00f6r styrelseledam\u00f6terna och den verkst\u00e4llande direkt\u00f6ren
10. Fastst\u00e4llande av arvoden till styrelsen och revisorn
11. Val till styrelsen och av revisor
12. Beslut om bemyndigande
13. Avslutande av bolagsst\u00e4mman<\/span><\/p>\n

F\u00f6rslag till beslut<\/span><\/strong><\/p>\n

Punkt 10 och 11<\/strong><\/span><\/p>\n

F\u00f6rslag till fastst\u00e4llande av arvode samt f\u00f6rslag till styrelse och revisor kommer att presenteras p\u00e5 bolagets hemsida den 18 maj 2016.<\/span><\/p>\n

Punkt 12<\/strong><\/span><\/p>\n

Styrelsen f\u00f6resl\u00e5r att \u00e5rsst\u00e4mman beslutar att bemyndiga styrelsen att, vid ett eller flera tillf\u00e4llen intill n\u00e4sta \u00e5rsst\u00e4mma, fatta beslut om nyemission h\u00f6gst 1\u00a0000\u00a0000 aktier med eller utan f\u00f6retr\u00e4desr\u00e4tt f\u00f6r aktie\u00e4garna. Styrelsens beslut f\u00e5r f\u00f6renas med villkor om att tecknade aktier f\u00e5r betalas genom kvittning.<\/span><\/p>\n

C. Upplysningar, handlingar och antal aktier och r\u00f6ster<\/strong><\/span><\/p>\n

Styrelsen och VD ska, om n\u00e5gon aktie\u00e4gare beg\u00e4r det och styrelsen anser att det kan ske utan v\u00e4sentlig skada f\u00f6r Bolaget l\u00e4mna upplysningar om f\u00f6rh\u00e5llanden som kan inverka p\u00e5 bed\u00f6mningen av ett \u00e4rende p\u00e5 dagordningen.<\/span><\/p>\n

Redovisningshandlingar och revisionsber\u00e4ttelse finns tillg\u00e4ngliga p\u00e5 Bolagets hemsida, www.nanexa.com, och p\u00e5 bolagets adress Virdings All\u00e9 32 B, 754 50 Uppsala, fr\u00e5n och med den 5 maj 2016. Kopior av dessa handlingar kommer att s\u00e4ndas till de aktie\u00e4gare som beg\u00e4r det och uppger sin postadress. Handlingarna kommer \u00e4ven att h\u00e5llas tillg\u00e4ngliga vid st\u00e4mman.<\/span><\/p>\n

Bolaget har 5\u00a0073 289 aktier och r\u00f6ster.<\/span><\/p>\n

_____________________<\/span><\/p>\n

Nanexa AB (publ)<\/span><\/p>\n

Styrelsen<\/em><\/span><\/p>\n

F\u00f6r mer information kontakta:<\/span><\/p>\n

David Westberg \u2013 VD, Nanexa AB (publ)\u00a0<\/span><\/p>\n

?Telefon: 0709 -42 83 03?<\/span><\/p>\n

E-post:\u00a0david.westberg@nanexa.se<\/span><\/p>\n

www.nanexa.se<\/a><\/span><\/p>\n

Om Nanexa AB (publ)<\/span><\/p>\n

Nanexa AB \u00e4r ett h\u00f6gteknologiskt forskningsf\u00f6retag som utvecklar och marknadsf\u00f6r produkter inom nanoteknologi. Bolagets fokus ligger p\u00e5 PharmaShell\u00ae som \u00e4r ett nytt och banbrytande drug delivery-system som bed\u00f6ms ha en stor potential inom ett flertal omr\u00e5den. Inom ramen f\u00f6r PharmaShell\u00ae har Nanexa samarbetsavtal med bland andra AstraZeneca och Karolinska Institutet.<\/span><\/p>\n

\n

Bifogade filer<\/strong><\/p>\n\n

<\/a><\/p>\n<\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

Aktie\u00e4garna i Nanexa AB(publ) kallas h\u00e4rmed till \u00e5rsst\u00e4mma i Nanexa AB (publ), 556833-0285, torsdagen den 26 maj 2016, klockan 17.00 p\u00e5 Uppsala Business Park, Rapsgatan 7, Uppsala.<\/p>\n","protected":false},"template":"","class_list":["post-3920","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-ci_sv","mfn-news-tag-mfn-ci-gm_sv","mfn-news-tag-mfn-type-ir_sv","mfn-news-tag-mfn-ci-gm-notice_sv","mfn-news-tag-mfn-regulatory-listing_sv","mfn-news-tag-mfn_sv","mfn-news-tag-mfn-regulatory_sv","mfn-news-tag-mfn-lang-sv_sv"],"acf":[],"yoast_head":"\nKallelse till \u00e5rsst\u00e4mma i Nanexa AB (publ) - Nanexa AB<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanexa.com\/mfn_news\/kallelse-till-arsstamma-i-nanexa-ab-publ-2\/\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Kallelse till \u00e5rsst\u00e4mma i Nanexa AB (publ) - Nanexa AB\" \/>\n<meta property=\"og:description\" content=\"Aktie\u00e4garna i Nanexa AB(publ) kallas h\u00e4rmed till \u00e5rsst\u00e4mma i Nanexa AB (publ), 556833-0285, torsdagen den 26 maj 2016, klockan 17.00 p\u00e5 Uppsala Business Park, Rapsgatan 7, Uppsala.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanexa.com\/mfn_news\/kallelse-till-arsstamma-i-nanexa-ab-publ-2\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanexa AB\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Ber\u00e4knad l\u00e4stid\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minuter\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/kallelse-till-arsstamma-i-nanexa-ab-publ-2\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/kallelse-till-arsstamma-i-nanexa-ab-publ-2\\\/\",\"name\":\"Kallelse till \u00e5rsst\u00e4mma i Nanexa AB (publ) - Nanexa AB\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\"},\"datePublished\":\"2016-04-28T14:51:01+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/kallelse-till-arsstamma-i-nanexa-ab-publ-2\\\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/kallelse-till-arsstamma-i-nanexa-ab-publ-2\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/kallelse-till-arsstamma-i-nanexa-ab-publ-2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Hem\",\"item\":\"https:\\\/\\\/nanexa.com\\\/sv\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MFN News Items\",\"item\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Kallelse till \u00e5rsst\u00e4mma i Nanexa AB (publ)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"name\":\"Nanexa AB\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanexa.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\",\"name\":\"Nanexa AB\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"sv-SE\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"contentUrl\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"width\":165,\"height\":50,\"caption\":\"Nanexa AB\"},\"image\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Kallelse till \u00e5rsst\u00e4mma i Nanexa AB (publ) - Nanexa AB","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanexa.com\/mfn_news\/kallelse-till-arsstamma-i-nanexa-ab-publ-2\/","og_locale":"sv_SE","og_type":"article","og_title":"Kallelse till \u00e5rsst\u00e4mma i Nanexa AB (publ) - Nanexa AB","og_description":"Aktie\u00e4garna i Nanexa AB(publ) kallas h\u00e4rmed till \u00e5rsst\u00e4mma i Nanexa AB (publ), 556833-0285, torsdagen den 26 maj 2016, klockan 17.00 p\u00e5 Uppsala Business Park, Rapsgatan 7, Uppsala.","og_url":"https:\/\/nanexa.com\/mfn_news\/kallelse-till-arsstamma-i-nanexa-ab-publ-2\/","og_site_name":"Nanexa AB","twitter_card":"summary_large_image","twitter_misc":{"Ber\u00e4knad l\u00e4stid":"3 minuter"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/nanexa.com\/mfn_news\/kallelse-till-arsstamma-i-nanexa-ab-publ-2\/","url":"https:\/\/nanexa.com\/mfn_news\/kallelse-till-arsstamma-i-nanexa-ab-publ-2\/","name":"Kallelse till \u00e5rsst\u00e4mma i Nanexa AB (publ) - Nanexa AB","isPartOf":{"@id":"https:\/\/nanexa.com\/#website"},"datePublished":"2016-04-28T14:51:01+00:00","breadcrumb":{"@id":"https:\/\/nanexa.com\/mfn_news\/kallelse-till-arsstamma-i-nanexa-ab-publ-2\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanexa.com\/mfn_news\/kallelse-till-arsstamma-i-nanexa-ab-publ-2\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/nanexa.com\/mfn_news\/kallelse-till-arsstamma-i-nanexa-ab-publ-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Hem","item":"https:\/\/nanexa.com\/sv\/"},{"@type":"ListItem","position":2,"name":"MFN News Items","item":"https:\/\/nanexa.com\/mfn_news\/"},{"@type":"ListItem","position":3,"name":"Kallelse till \u00e5rsst\u00e4mma i Nanexa AB (publ)"}]},{"@type":"WebSite","@id":"https:\/\/nanexa.com\/#website","url":"https:\/\/nanexa.com\/","name":"Nanexa AB","description":"","publisher":{"@id":"https:\/\/nanexa.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanexa.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"},{"@type":"Organization","@id":"https:\/\/nanexa.com\/#organization","name":"Nanexa AB","url":"https:\/\/nanexa.com\/","logo":{"@type":"ImageObject","inLanguage":"sv-SE","@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","contentUrl":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","width":165,"height":50,"caption":"Nanexa AB"},"image":{"@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/mfn_news\/3920","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/media?parent=3920"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}